Construction of a Nomogram Model for Predicting Pathologic Complete Response in Breast Cancer Neoadjuvant Chemotherapy Based on the Pan-Immune Inflammation Value
Current Oncology · 2025
DOI: 10.3390/curroncol32040194 ↗Kurz gefasst
Multizentrische Studie in der Zeitschrift Current Oncology, 2025. Verfasst von Zhuowan Tian und 6 weiteren Autor:innen. Beteiligte Einrichtung: Hubei Key Laboratory of Tumor Biological Behaviors, Department of Breast and Thyroid Surgery, Hubei Cancer Clinical Study Center, Zhongnan Hospital, …. Hauptthemen laut MEDLINE: Breast Neoplasms, Inflammation, Neoadjuvant Therapy, Nomograms. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 36 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Themen: Onkologische Pflege
Abstract (Originalsprache)
Background
The pan-immune inflammation value (PIV) has unclear predictive utility for pathologic complete response (pCR) in breast cancer patients undergoing neoadjuvant chemotherapy (NAC). This study aimed to evaluate the PIV’s predictive value and develop a nomogram integrating PIV for individualized pCR prediction.
Methods
In a retrospective multicenter study of 507 NAC-treated patients (training cohort: 357; validation cohort: 150), independent predictors of pCR were identified through univariate and multivariate logistic regression. A nomogram was constructed and validated using receiver operating characteristic (ROC) curves, calibration curves, and decision curve analysis (DCA). Net reclassification improvement (NRI) and integrated discrimination improvement (IDI) evaluated the improvement in performance after incorporating the PIV indicator.
Results
The high PIV patients (cutoff: 316.533) had significantly lower pCR rates than the low PIV patients (p < 0.001). The nomogram incorporating PIV, estrogen receptor (ER), human epidermal growth factor receptor-2 (Her2), tumor diameter, clinical node stage, and chemotherapy regimen showed excellent discrimination (training cohort area under the curve (AUC): 0.861, 95% confidence interval (CI): 0.821–0.901; validation cohort AUC: 0.815, 95% CI: 0.748–0.882). The calibration curves demonstrate high prediction accuracy (Hosmer–Lemeshow test: p > 0.05), while DCA, NRI (0.341, 95% CI: 0.181–0.500), and IDI (0.017, 95% CI: 0.004–0.029) confirm clinical utility.
Conclusions
The PIV is an independent predictor of pCR, and the PIV-based nomogram provides a reliable tool for optimizing NAC response prediction in breast cancer.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Hubei Key Laboratory of Tumor Biological Behaviors, Department of Breast and Thyroid Surgery, Hubei Cancer Clinical Study Center, Zhongnan Hospital, Wuhan University, Wuhan 430071, China.
- Department of Head and Neck Surgery, Hubei Cancer Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan 430079, China.
- Hubei Provincial Key Laboratory of Developmentally Originated Disease, Department of Pathology and Pathophysiology, School of Basic Medical Sciences, Wuhan University, Wuhan 430071, China.
ORCID-Profile: Zhuowan Tian
Zitieren
APA
Tian, Z., Xi, Y., Chen, M., Hu, M., Chen, F., Wei, L., & Zhang, J. (2025). Construction of a Nomogram Model for Predicting Pathologic Complete Response in Breast Cancer Neoadjuvant Chemotherapy Based on the Pan-Immune Inflammation Value. Current Oncology. https://doi.org/10.3390/curroncol32040194
Vancouver
Tian Z, Xi Y, Chen M, Hu M, Chen F, Wei L, et al. Construction of a Nomogram Model for Predicting Pathologic Complete Response in Breast Cancer Neoadjuvant Chemotherapy Based on the Pan-Immune Inflammation Value. Current Oncology. 2025. doi:10.3390/curroncol32040194
BibTeX
@article{Tian2025,
author = {Tian, Zhuowan and Xi, Yiqing and Chen, Mengting and Hu, Meishun and Chen, Fangfang and Wei, Lei and Zhang, Jingwei},
title = {Construction of a Nomogram Model for Predicting Pathologic Complete Response in Breast Cancer Neoadjuvant Chemotherapy Based on the Pan-Immune Inflammation Value},
journal = {Current Oncology},
year = {2025},
doi = {10.3390/curroncol32040194}
}
EUVIMED